Pregnancy Related Clinical Trial
— SLEEPOfficial title:
SLEEP: Sleep Disordered Breathing, Endothelial Function, and Adverse Events in Pregnancy
NCT number | NCT05908591 |
Other study ID # | Pro00110658 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2023 |
Est. completion date | August 2024 |
This is a prospective longitudinal cohort study whereby pregnant individuals are asked to complete an 8-day testing protocol to measure their sleep and cardiovascular health at two timepoints during pregnancy.
Status | Recruiting |
Enrollment | 109 |
Est. completion date | August 2024 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - over 18 years of age - pregnant (20-24 weeks gestation at enrollment) Exclusion Criteria: - worked shift work past 11pm in the previous month - previously diagnosed with a sleep disorder by a physician |
Country | Name | City | State |
---|---|---|---|
Canada | Program for Pregnancy and Postpartum Health, University of Alberta | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Alberta |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Endothelial Function | The investigators will assess endothelial function using flow mediated dilation | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Cardiovascular Function - arterial stiffness with pulse wave velocity | The investigators will measure arterial stiffness using pulse wave velocity of the carotid and femoral arteries | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Cardiovascular Function - arterial stiffness with beat-by-beat blood pressure | The investigators will measure arterial stiffness using beat-by-beat blood pressure from the finger. | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Cardiovascular Function - ambulatory blood pressure | Blood pressure will be collected every 30 minutes during a 24-hour period using an ambulatory blood pressure monitor. | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Cardiovascular Function - resting blood pressure | Beat-by-beat blood pressure will be collected at rest. | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Cardiovascular Function - heart rate | Heart rate will be assessed by 3-lead ECG collected during sleep and at rest. | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Cardiovascular Function - arrythmias | Presence of arrythmias will be assessed by 3-lead ECG collected during sleep and at rest. | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Maternal outcome - dietary intake | Participants will complete two 3-day food logs. | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Fasted blood sample - blood viscosity | Fasted blood samples will be analyzed using a viscometer. | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Fasted blood sample - presence of inflammatory markers | Fasted blood samples will be analyzed for C-reactive protein. | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Fasted blood sample - sex hormone levels | Fasted blood samples will be analyzed for sex hormone levels (estrogen, progesterone, testosterone). | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Fasted blood sample - metabolic | Fasted blood samples will be analyzed for glucose and insulin concentration. | 20-24 weeks and 28-36 weeks gestation | |
Secondary | Maternal outcomes - delivery | Participants will provide the investigators with information regarding delivery and pregnancy complications (gestational diabetes, pregnancy induced hypertension, preeclampsia). | 2 months postpartum | |
Secondary | Fetal outcomes at delivery - infant sex | Participants will provide the investigators with information regarding infant sex. | 2 months postpartum | |
Secondary | Fetal outcomes at delivery - birth weight | Participants will provide the investigators with information regarding infant birth weight. | 2 months postpartum | |
Secondary | Fetal outcomes at delivery - birth length | Participants will provide the investigators with information regarding birth length. | 2 months postpartum | |
Secondary | Fetal outcomes at delivery - gestational age | Participants will provide the investigators with information regarding gestational age at delivery. | 2 months postpartum | |
Secondary | Fetal outcomes at delivery - birth mode | Participants will provide the investigators with information regarding birth mode. | 2 months postpartum | |
Secondary | Fetal outcomes at delivery - apgar score | Participants will provide the investigators with information regarding infant apgar score at delivery. | 2 months postpartum | |
Secondary | Fetal outcomes at delivery - time spent in NICU | Participants will provide the investigators with information regarding infant time spent in neonatal intensive care unit (NICU). | 2 months postpartum | |
Secondary | Maternal outcome - amount of activity | Participants will wear two accelerometers to measure the amount of physical activity performed. | 20-24 weeks and 28-36 weeks | |
Secondary | Maternal outcome - Mood - State-Trait Anxiety Inventory | Participants will complete the State-Trait Anxiety Inventory to measure mood. | 20-24 weeks and 28-36 weeks | |
Secondary | Maternal outcome - Mood - Edinburgh Postnatal Depression Scale | Participants will complete the Edinburgh Postnatal Depression Scale to measure mood. | 20-24 weeks and 28-36 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05017974 -
Research on Improving Sleep During Pregnancy
|
N/A | |
Completed |
NCT03284515 -
Vaccination In Pregnancy Gene Signature: VIP Signature Study
|
||
Recruiting |
NCT05969795 -
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
|
Phase 1 | |
Recruiting |
NCT06051201 -
Innovation for Small-scale Experiments: ReceptIVFity Test
|
N/A | |
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Enrolling by invitation |
NCT04527926 -
STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy
|
N/A | |
Recruiting |
NCT04278651 -
Early Antenatal Support for Iron Deficiency Anemia
|
Phase 4 | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT06258902 -
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
|
||
Completed |
NCT05487196 -
Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia
|
Phase 2 | |
Completed |
NCT03750968 -
Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects
|
Phase 2 | |
Enrolling by invitation |
NCT06127277 -
Next4You: A Fully Mobile Relationships Based Program for Youth in Foster Care
|
N/A | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Recruiting |
NCT05899101 -
The Impact of Opioid and Cannabis Exposure on Fetal Growth
|
||
Completed |
NCT05502510 -
Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
|
||
Completed |
NCT04296396 -
Opioid Prescription After Cesarean Trial
|
Phase 3 | |
Not yet recruiting |
NCT06069856 -
Multiple Micronutrient Supplementation (MMS) IFA- Iron Dose Acceptability Crossover Trial
|
Phase 3 | |
Not yet recruiting |
NCT06069869 -
Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial
|
Phase 3 | |
Not yet recruiting |
NCT06079918 -
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
|
Phase 3 | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A |